StockNews.com Lowers Integra LifeSciences (NASDAQ:IART) to Hold

Integra LifeSciences (NASDAQ:IART) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other research firms have also weighed in on IART. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Truist Financial cut their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Finally, JMP Securities cut their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Price Performance

IART stock traded down $0.07 during midday trading on Tuesday, hitting $29.17. The company’s stock had a trading volume of 650,226 shares, compared to its average volume of 702,239. Integra LifeSciences has a 12 month low of $27.18 and a 12 month high of $56.21. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of 35.14, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12. The company has a 50 day moving average of $35.02 and a two-hundred day moving average of $38.71.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same quarter in the previous year, the company earned $0.94 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts expect that Integra LifeSciences will post 3.19 EPS for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. Raymond James & Associates grew its stake in Integra LifeSciences by 28.7% in the third quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after purchasing an additional 45,554 shares during the last quarter. Strs Ohio grew its stake in Integra LifeSciences by 6.9% in the third quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock valued at $1,593,000 after purchasing an additional 2,679 shares during the last quarter. Advisor Partners II LLC purchased a new position in Integra LifeSciences in the third quarter valued at about $241,000. Inspire Investing LLC grew its stake in Integra LifeSciences by 5.1% in the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after purchasing an additional 392 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Integra LifeSciences by 451.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock valued at $2,705,000 after acquiring an additional 57,993 shares during the period. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.